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ABSTRACT
Awareness and reporting of mesh-related
complications of pelvic organ prolapse repairs
have increased in recent years. As a result,
deciding whether to use a mesh or not has
become a difficult task for urogynecologists.
Our aim was to summarize reasons for and
against the use of mesh in prolapse repair based
on a review of relevant literature. Scopus and
PubMed databases were searched for papers
reporting on the efficacy and safety of native
tissue versus non-absorbable, synthetic mesh
prolapse repairs. Randomized controlled trials,
systematic reviews, and meta-analyses were
included. Evidence is presented for each
vaginal compartment separately. In the
anterior compartment, mesh repairs seem to
offer clearly superior efficacy and durability of
results compared to native tissue repairs, but
with an equally clear increase in complication
rates. In the isolated posterior compartment
prolapse, high-quality evidence is sparse. As far
as the apical compartment is concerned,
sacrocolpopexy is the most efficacious, yet
the most invasive procedure. Data on the
comparison of transvaginal mesh versus
native tissue repairs of the apical
compartment are somewhat ambiguous.
Given the inevitable coexistence of
advantages and disadvantages of mesh use in
each of the prolapsed vaginal compartments,
an individualized treatment decision, based on
weighing risks against benefits for each patient,
seems to be the most rational approach.
Keywords: Anterior compartment; Apical
compartment; Mesh repair; Native tissue
repair; Non-absorbable synthetic mesh; Pelvic
organ prolapse; Posterior compartment;
Urology
INTRODUCTION
Pelvic organ prolapse (POP) is the sign of
descent of one or more of the following: the
anterior vaginal wall, the posterior vaginal wall,
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the uterus (cervix) or the apex of the vagina
(vaginal vault or cuff scar after hysterectomy)
[1]. Its prevalence is currently estimated to be
approximately 40% in women 45–85 years of
age, and around 30% of these women are
symptomatic [2]. Symptomatic patients may
complain of urinary, bowel, or sexual
symptoms as well as symptoms of vaginal
pressure, heaviness, or pain [3]. These
symptoms have a major impact on patients’
physical and emotional well-being [4].
The pelvic organs can descend, as mentioned
in the definition, in any of the three different
anatomical compartments: the anterior, the
posterior, and the apical, or in more than one
compartment. The degree of pelvic organ
descent was initially quantified using the
Baden–Walker halfway scoring system [5].
However, the POP-Q grading system [6], with
proven interobserver and intraobserver
reliability [7], is more commonly used in the
literature in the past few years [8].
Treatment of POP is commonly surgical [9]
and the lifetime risk of undergoing a pelvic
reconstruction surgery is estimated at about
11.8% by the age of 80 years [10]. The surgical
prolapse repair aims primarily at restoring the
anatomy of the structures supporting the
pelvic organs. These structures have been
described and classified in three different
levels in the landmark paper by DeLancey
[11].
Several techniques are available for pelvic
organ prolapse repair. Depending on the
material used to restore pelvic organ support,
these techniques are classified as ‘‘native tissue
repairs’’ when only pelvic organ support tissues
are used or ‘‘reinforced or augmented repairs’’
when some other material is used to reinforce
the defective support system. These include
autologous or heterologous biological or
synthetic, absorbable or non-absorbable,
materials. As native tissue repairs showed
discouraging rates of surgical failure in early
studies [12, 13], reinforced repairs, using
mainly synthetic mesh materials, became
more popular [14]. This trend was facilitated
by the marketing of numerous mesh kits
(containing meshes and special introducing
instruments), which were mainly used by the
transvaginal route [15]. Approximately a
decade later, complications of mesh usage
started to emerge [16], leading to the US Food
and Drug Administration (FDA) safety
warnings regarding mesh complications,
especially for meshes placed transvaginally
[17].
Given the dilemmas regarding mesh use in
pelvic reconstructive surgery, we aimed to
summarize reasons for and against it based on
a review of the current literature. The literature
search was conducted in Scopus and PubMed
databases until May 2016, for English-language
papers on the efficacy and safety of native tissue
versus non-absorbable, synthetic mesh prolapse
repairs. Randomized controlled trials were
included. Results of systematic reviews and
meta-analyses were also included without
reporting individual trials, for reasons of
brevity. As the balance of benefits and
disadvantages from native tissue or mesh
augmented repairs may vary according to the
prolapsed compartment, evidence is organized
under anterior, posterior, and apical
compartment prolapse.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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RESULTS
Anterior Compartment Prolapse
Reasons For Using a Mesh
The main argument for using a mesh in the
anterior repair would be its superior efficacy and
durability in treating the signs and symptoms of
prolapse, compared to native tissue repairs, with
fewer recurrences and reoperations.
In the 2016 Cochrane systematic review on
transvaginal permanent mesh repair versus
native tissue repair [18], 15 trials were
included in the meta-analysis of data
concerning the anterior compartment:
recurrent prolapse was demonstrated in 12.2%
(107/870) of the patients who underwent a
mesh repair compared to 39.6% (348/878) of
the patients who underwent an anterior
colporrhaphy (RR 0.33 and Tau2 = 0.02,
Chi2 = 15.51, I2 = 10%).
The high anatomic cure rates of around 90%
with mesh repairs were evident in early mesh
studies [19–21] and were later confirmed by
several others [22–25]. A recent multicenter
randomized controlled study compared the
Avaulta Plus anterior biosynthetic mesh
procedure, with anterior colporrhaphy in a
total of 138 women (70 and 68 women,
respectively) [26]. The patients were 55 years
old or older and had at least stage 2 anterior
vaginal wall prolapse according to the POP-Q
system. Anatomical success was defined as less
than stage 2. At 3 years follow-up, the objective
anatomic cure rate was 91.4% for the mesh
group and 41.2% for the colporrhaphy group. A
more recent randomized study also showed a
significant difference of efficacy between the
trocar-guided Nazca TC kit and anterior
colporrhaphy groups [27]. The trial reported
on 86 patients with an anterior compartment
prolapse stage 2 or more, according to the
POP-Q system. The anatomical success rates,
defined as Ba\0, were 74.4% and 51.1% at
2 years follow-up (p = 0.022), for the mesh and
native tissue repair groups, respectively.
Apart from superior objective efficacy, using
a mesh seems to offer better prolapse symptom
improvement, compared to native tissue
repairs. In a prospective randomized
controlled study, 68 patients were randomized
into a native tissue repair group (n = 35) and the
Perigee transobturator anterior compartment
repair system (n = 33) [28]. Patients had POP-Q
stage 3 or 4 anterior compartment prolapse.
Subjective awareness of prolapse was one of the
study’s secondary outcomes. At 2 years
follow-up, 5 out of 33 women in the mesh
group (15.1%) were aware of the prolapse
compared to 9 out of 35 women in the
colporrhaphy group (25.7%). Similar results
have been published by several previous
randomized studies in the last 5 years [29–32].
The higher rates of objective and subjective
cure rates with mesh repairs lead to lower rates
of repeat surgery for prolapse. In a randomized
controlled study, 201 patients underwent an
anterior colporrhaphy or a mesh repair using
the transobturator Ugytex mesh (97 and 104
patients, respectively) [32]. The follow-up was
set at 3 years, the recurrence of the prolapse was
the primary endpoint, and the reoperation rate
for prolapse was a secondary endpoint of the
study. The authors found superior outcomes
with mesh repair both for prolapse recurrence
and reoperation. In the mesh group, 5.7% (6/
104) women were reoperated on for recurrent
prolapse compared to 10.3% (10/97) in the
anterior colporrhaphy group. Similar results
were published by another randomized
controlled trial with short-term follow-up
(6 months), where 56 women underwent a
native tissue repair and 58 women a mesh
repair for the anterior compartment [33]. While
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the primary endpoint of the study was sexual
function, the study included the reoperation
rate for prolapse as a secondary outcome: it was
7.1% (4/56 patients) in the native tissue repair
group and 5.1% (3/58 patients) in the mesh
group.
Reasons Against Using a Mesh
The main reason for not using a mesh in the
anterior compartment is mesh-related
complications including, primarily, mesh
exposure for which a woman undergoing a
native tissue repair has no risk. In the most
recentmeta-analysis of transvaginal mesh versus
native tissue repairs, 14 randomized trials for the
anterior compartment repair were analyzed [18].
The meta-analysis showed that mesh exposure
was noted in 10.1% (76/753) of women after
anterior mesh repair. In the same meta-analysis,
15 randomized trials (933women)were included
in the analysis for the rate of surgical
intervention for mesh exposure in the anterior
compartment. It was found that 7.7% (72/933) of
women who underwent a mesh repair also had
surgery for mesh exposure. This evidence is
further supported by recent studies [26, 27].
Another reason against the use of meshes is
the apparently increased rates of de novo stress
urinary incontinence with mesh repairs in the
anterior compartment. The most recent
Cochrane review analyzed 12 randomized
trials of transvaginal mesh repair versus native
tissue repair to estimate the incidence of new
stress urinary incontinence after surgery [18].
The follow-up of the studies was 1–3 years. The
meta-analysis showed that 133 per 1000 women
developed de novo stress urinary incontinence
after mesh surgery compared to 96 per 1000
women after a native tissue repair. These
findings are further supported by a recently
published randomized controlled trial with a
follow-up of 3 years [26]. Seventy women
underwent anterior prolapse surgery using the
Avaulta Plus anterior biosynthetic mesh
procedure and 68 women anterior
colporrhaphy. Despite the higher anatomic
cure rates in the mesh group, the rates of de
novo stress urinary incontinence were lower in
the anterior colporrhaphy group: 1.4% (1 of 68
patients) compared to 8.5% (6 of 70 patients) in
the mesh group.
The increased rate of intraoperative bladder
injury is another reason against using a mesh.
This is supported by the results of a multicenter,
parallel-group randomized controlled trial
comparing a trocar-guided, transvaginal
transobturator polypropylene-mesh repair kit,
the Gynecare Prolift Anterior Pelvic Floor
Repair System, with anterior colporrhaphy
[31]. The authors used the POP-Q system to
quantify prolapse and set a composite
anatomical and a functional outcome for
efficacy evaluation: both Ba\-1 and
subjective absence of vaginal bulging. A total
of 389 patients were included, with 200 women
undergoing the mesh kit repair and 189 women
the anterior colporrhaphy. Despite a higher rate
of success for the mesh group, bladder injury
rate was lower in the colporrhaphy group: 0.5%
(only 1 out of 183 patients) in the colporrhaphy
group compared to 3.7% (7 out of 186 women)
in the mesh group.
Posterior Compartment Prolapse
Similar to anterior compartment prolapse
repair, the main argument for mesh use in the
posterior compartment would be superior
efficacy and durability of results, compared to
native tissue repairs. Mesh-related
complications would be the main argument
against mesh use.
Several prospective and retrospective case
series have demonstrated the high efficacy and
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safety of either mesh-augmented [34] or native
tissue repairs [35–39]. Success rates in the range
of 76–88% have been described, depending on
the definition of success and length of
follow-up.
Our literature search did not return any
randomized controlled trials comparing
permanent mesh repair with native tissue
repair in isolated posterior compartment
prolapse. Nevertheless, indirect data for the
posterior compartment are available from
randomized trials of patients with
multicompartment prolapse, where restoration
of apical support was the primary outcome. She
2016 Cochrane systematic review and
meta-analysis [18] summarized the results of
three trials [40–42] of apical prolapse repairs,
with optional concomitant anterior/posterior
repairs, where follow-up data on the posterior
compartment were reported. Data showed no
statistically or clinically significant difference in
objective failure rates in the posterior
compartment between mesh and no mesh
repairs of multicompartment prolapse: failure
rate was 7.4% (8 of 107 repairs) with mesh
repairs compared to 11.7% (14 of 119 repairs)
with native tissue repairs (p = 0.92).
Apical Compartment Prolapse
(Uterine-Vaginal Apex Vault)
The main argument for using a mesh to
reinforce apical compartment prolapse repairs
is the same as in other compartments: its
superior efficacy and durability in treating
prolapse, compared to native tissue repairs,
with fewer recurrences and reoperations. An
increased rate of adverse events would similarly
be an argument against use of mesh.
Nevertheless, the apical compartment
represents some particularities in comparison
to the others. The first is that because of the
anatomical configuration of the pelvic organ
support system [11], prolapse of the vaginal
apex is frequently associated with defects in the
anterior and posterior vaginal compartments.
The second one is that there are two completely
different modes of applying the mesh: the
abdominal route and the vaginal route.
Placing a mesh transabdominally, i.e.,
performing a sacrocolpopexy, can be done
through open, laparoscopic or robotic-assisted
approaches. Native tissue prolapse repairs are
done transvaginally and include McCall’s
culdoplasty/sacrospinous ligament fixation
(SSLF), iliococcygeus fixation (ICS), and
uterosacral ligament suspension (USLS).
Because of the differences in the very nature of
the surgical procedures, sacrocolpopexy and
transvaginal mesh repairs are considered, and
compared to native tissue repairs, separately
below.
Mesh Sacrocolpopexy Versus Native Tissue
Repairs
The 2013 Cochrane review on the surgical
management of pelvic organ prolapse [9]
reported five randomized controlled trials
comparing sacrocolpopexy (open) to native
tissue repairs. In four out of the five trials
success rates were better for sacrocolpopexy:
they ranged from 59% to 100% while they were
28–82% in native tissue repairs. Only one trial
[43] reported better outcomes with native tissue
repair: 87% with uterosacral ligament fixation
versus 68% with open sacrocolpopexy. It has to
be mentioned though that the outcome in this
trial was subjective improvement of prolapse
symptoms and that vaginal hysterectomy in the
native tissue group was compared to uterine
preservation in the abdominal group. On the
basis of the above evidence, the authors of the
Cochrane review concluded that
sacrocolpopexy offers higher correction rates
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for apical vaginal prolapse compared to native
tissue procedures. This conclusion was
confirmed by another systematic review and
meta-analysis of sacrocolpopexy versus native
tissue repair published in 2015 [44].
Efficacy data from the aforementioned
meta-analyses suggest that abdominal
sacrocolpopexy may be preferred in
comparison to native tissue repairs. However,
for open sacrocolpopexy operating and recovery
time was longer and cost was higher, compared
to native tissue procedures. Adverse events were
also more frequent: compiled data from 79
studies [44] showed higher incidences of bowel
(2.7% compared to 0.2%, p\0.01), mesh and
suture (4.2% compared with 0.4%, p\0.01),
and thromboembolic adverse events (0.6%
compared with 0.1%, p = 0.03) after mesh
sacrocolpopexy compared with native tissue
vaginal repairs. In sacrocolpopexy trials
included in the 2013 Cochrane review, mesh
exposure rates ranged from 2% to 10.7%.
Furthermore, sacrocolpopexy may not be
suitable for patients with significant medical
and surgical comorbidities. Minimally invasive
sacrocolpopexy, either laparoscopic or
robot-assisted, promises to reduce limitations
and adverse events of the open approach but
relevant evidence has not yet matured [45] and
such a comparison is beyond the scope of the
present review.
Transvaginal Mesh Versus Native Tissue
Repairs
The efficacy and safety of transvaginal
mesh-augmented repairs compared to vaginal
native tissue repairs for middle- or
multi-compartment prolapse have been
reported in four randomized controlled trials.
In 2012, outcomes of a double-blind,
multicenter randomized controlled trial
comparing traditional vaginal prolapse surgery
without mesh and mesh repairs in patients with
symptomatic POP-Q stage 2–4 prolapse were
published [46]. No-mesh operations included
anterior or posterior colporrhaphy, or both;
uterosacral ligament suspension; or
sacrospinous ligament fixation. Repair with
mesh included synthetic mesh implant kits
such as Anterior ProliftTM, Modified Anterior
ProliftTM with apical arms, or Total ProliftTM.
Sixty-five operations (33 mesh/32 no mesh)
were done before the trial was halted as a
result of a mesh exposure rate of 15.6% which
did not match the predetermined safety criteria.
At 12 months postoperatively, mesh use
resulted in a higher reoperation rate and did
not improve cure rates. Three-year follow-up
data of the same trial were reported in 2013
[47]. Objective cure, defined as a composite of
no prolapse beyond the hymen and adequate
apical support, was 85% and 71% for mesh and
no mesh, respectively, a difference that was not
statistically significant (p = 0.45). Subjective
cure, including lack of symptoms and
satisfaction, was high in both groups, also
with no statistical significance between them.
A multicenter randomized controlled study
compared prolapse recurrence and
complication rates for ProliftTM mesh repair
and sacrospinous fixation in the treatment of
post-hysterectomy vaginal vault prolapse [48]. A
total of 168 patients were randomized, 85 to the
mesh and 83 to the native tissue repair groups,
respectively. Prolapse recurrence 1 year
postoperatively was noted in 16.9% of the
mesh group compared to 39.4% in the native
tissue repair group (p = 0.003). The mesh
exposure rate was 20.8%.
In 2014, another single-center, randomized
trial compared the transvaginal mesh procedure
Prolift Total with sacrospinous fixation for
post-hysterectomy vaginal vault prolapse [49].
Seventy patients with at least two-compartment
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prolapse were randomized into the mesh
(n = 36) or the native tissue repair (n = 34)
groups. One of the primary outcomes of the
study was anatomical failure defined as prolapse
to the level of the hymen or below at clinical
examination. At 1-year follow-up anatomical
failures were significantly less common in the
mesh group: 3% (only one case) versus 65% (22
cases) in the native tissue repair group
(p\0.001). There were three cases (8%) of
minor mesh exposure.
One more multicenter, randomized trial
compared the polypropylene mesh repair
ProliftTM to sacrospinous ligament fixation for
apical defects as well other, site-specific, native
tissue repairs in 184 women with POP-Q
prolapse stage 3 or 4 [50]. Ninety-four patients
underwent the mesh repair and 90 the native
tissue repair. Prolapse was considered cured
when the POP-Q point evaluation was equal to
or less than 0 and POP-Q point C better than or
equal to half the total vaginal length. At 1-year
follow-up, anatomical cure rates were better in
the mesh group in the anterior compartment
(86.4% versus 70.4%, p = 0.019) but there was
no statistically significant difference as far as the
apical compartment is concerned (92% versus
84%, p = 0.165). There were 18 patients with
mesh exposure (20%).
DISCUSSION
The main advantage of mesh-augmented pelvic
reconstruction is superior efficacy and
durability of results compared to native tissue
repairs. Indeed, the majority of studies confirm
the benefits of mesh use in terms of increased
success rates.
Nevertheless, interpreting such evidence and
using it in clinical decision-making are not
straightforward. First of all, there is significant
variation in the definition of surgical success
among studies [51]. Using different outcomes
may have considerable impact on the results
even of a single study. As an example, in a recent
randomized controlled trial comparing vaginal
mesh repair to anterior colporrhaphy, anatomic
cure rates were 74.4% and 51.1%, respectively at
2 years, but dropped to 40% for each group when
the definition of a successful outcome was
changed from postoperative prolapse POP-Q
stage 2 or less to stage 1 or less [27].
Caution is also advised when reoperation
rates are interpreted as a measure of success.
Very often reoperation rates for mesh repairs
include procedures for stress urinary
incontinence and mesh complications in
addition to those for prolapse recurrence. The
2016 Cochrane systematic review and
meta-analysis on vaginal prolapse repairs [18],
for example, showed a significantly higher
reoperation rate with mesh procedures (11.4%
versus 4.8% with native tissue repairs) but this
was driven predominantly, even though not
exclusively, by reoperations due to mesh-related
complications: reoperations for prolapse
recurrences, specifically, were only slightly
more common with mesh repairs (3.2% versus
1.7% in the native tissue group) while
anti-incontinence procedures were similar
(2.8% in the mesh group and 2.6% in the
native tissue group).
Another issue when interpreting literature
results on efficacy of repairs is that there is not a
direct and predictable relationship between
objective anatomical cure and subjective
improvement of prolapse symptoms or overall
patient satisfaction. Hopefully, future trials will
indicate ‘‘how much anatomical correction’’ is
needed if we are aiming primarily for satisfied
women.
The increased efficacy of mesh-augmented
repairs over native tissue ones comes with a cost
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of increased complications. Mesh exposure, in
particular, is a mesh-specific complication and
represents the most important safety concern.
Fear of this complication has considerably
altered clinical practice in recent years. It has
to be admitted that mesh complications may
have significant negative impact on patients’
quality of life and require multiple, on
occasions, complex operations for their
management. On the other hand, it has to be
argued that not all mesh exposures require
surgical intervention. Many of those are
asymptomatic and are discovered incidentally
during regular follow-up clinical examinations.
In most cases such asymptomatic exposures do
not require a surgical intervention and, in fact,
the American Association of Urology
recommends against mesh removal in
asymptomatic patients [52].
As there are pros and cons in using a mesh in
each vaginal compartment repair, the question
whether to use it or not should be answered on
an individual basis. When there is higher risk
for prolapse recurrence, it becomes more
reasonable to use a mesh repair. Prolapse
stage 3 or 4 (POP-Q), age less than 60 years,
diabetes mellitus, and recurrent prolapse are all
factors associated with increased failure of
native tissue repairs [53] and should be taken
into consideration. On the other hand, it is of
paramount importance to minimize
complications, mesh exposure in particular,
when mesh is used. Surgeon- and
patient-related risk factors should be carefully
addressed [54, 55].
Appropriate patient selection and
information are the only current means of
overcoming the dilemmas regarding the use of
mesh in prolapse repairs. Data from ongoing
and future trials will hopefully provide
information for safer evidence-based decisions.
CONCLUSION
In the anterior compartment, mesh repairs are
associated with better objective and subjective
results, compared to native tissue repairs. In
the same compartment, mesh-related
complications, higher rates of de novo stress
incontinence, and bladder injury are
arguments against use of mesh. With regards
to isolated posterior compartment prolapse,
lack of high-quality evidence does not allow
us to reach safe conclusions. In the apical
compartment, sacrocolpopexy offers better
results compared to the other surgical options
and causes fewer mesh-related complications
than transvaginal procedures, but is an
invasive procedure. Minimally invasive,
laparoscopic or robot-assisted, sacrocolpopexy
promises to reproduce results of the open
procedure.
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